Literature DB >> 35298646

Modelling futility in the setting of fertility treatment.

Alex Polyakov1,2,3, Christopher Gyngel4,5, Julian Savulescu5,6.   

Abstract

When is a fertility treatment futile? This question has great practical importance, given the role futility plays in ethical, legal and clinical discussions. Here, we outline a novel method of determining futility for IVF treatments. Our approach is distinctive for considering the economic value attached to the intended aim of IVF treatments, i.e. the birth of a child, rather than just the effects on prospective parents and the health system in general. We draw on the commonly used metric, quality-adjusted life years (QALYs), to attach a monetary value to new lives created through IVF. We then define futility as treatments in which the chance of achieving a live birth is so low that IVF is no longer a cost-effective intervention given the economic value of new births. This model indicates that IVF treatments in which the chance of a live birth are <0.3% are futile. This suggests IVF becomes futile when women are aged between 47 and 49 years of age. This is notable older than ages currently considered as futile in an Australian context (∼45). In the UK, government subsidized treatment with the couple's own gametes stops at the age of 42, while privately funded treatments are self-regulated by individual providers. In most European countries and the USA, the 'age of futility' is likewise managed by clinical consensus.
© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  assisted reproduction; bioethics; cost-effectiveness; futility; mathematical modelling; quality-adjusted life years

Mesh:

Year:  2022        PMID: 35298646      PMCID: PMC9071221          DOI: 10.1093/humrep/deac051

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.353


  24 in total

Review 1.  The costs and consequences of assisted reproductive technology: an economic perspective.

Authors:  Mark P Connolly; Stijn Hoorens; Georgina M Chambers
Journal:  Hum Reprod Update       Date:  2010-06-08       Impact factor: 15.610

2.  Harm isn't all you need: parental discretion and medical decisions for a child.

Authors:  Dominic Wilkinson; Tara Nair
Journal:  J Med Ethics       Date:  2015-12-18       Impact factor: 2.903

Review 3.  Post-neonatal health and development of children born after assisted reproduction: a systematic review of controlled studies.

Authors:  A K Ludwig; A G Sutcliffe; K Diedrich; M Ludwig
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2006-04-18       Impact factor: 2.435

4.  Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause.

Authors:  M J Faddy; R G Gosden; A Gougeon; S J Richardson; J F Nelson
Journal:  Hum Reprod       Date:  1992-11       Impact factor: 6.918

5.  How much are Americans willing to pay for a quality-adjusted life year?

Authors:  Milton C Weinstein
Journal:  Med Care       Date:  2008-04       Impact factor: 2.983

6.  Is futility a futile concept?

Authors:  B A Brody; A Halevy
Journal:  J Med Philos       Date:  1995-04

Review 7.  Acceptable cost for the patient and society.

Authors:  Georgina M Chambers; G David Adamson; Marinus J C Eijkemans
Journal:  Fertil Steril       Date:  2013-08       Impact factor: 7.329

8.  What does "futility" mean? An empirical study of doctors' perceptions.

Authors:  Ben White; Lindy Willmott; Eliana Close; Nicole Shepherd; Cindy Gallois; Malcolm H Parker; Sarah Winch; Nicholas Graves; Leonie K Callaway
Journal:  Med J Aust       Date:  2016-05-02       Impact factor: 7.738

9.  Expensive care? Resource-based thresholds for potentially inappropriate treatment in intensive care.

Authors:  Dominic Wilkinson; Stavros Petrou; Julian Savulescu
Journal:  Monash Bioeth Rev       Date:  2018-07

10.  Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients.

Authors:  Sandro C Esteves; Hakan Yarali; Lan N Vuong; José F Carvalho; İrem Y Özbek; Mehtap Polat; Ho L Le; Toan D Pham; Tuong M Ho; Peter Humaidan; Carlo Alviggi
Journal:  Hum Reprod       Date:  2021-07-19       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.